[Plasma levels, renal excretion and metabolism of orciprenaline after administration in sustained-release form (author's transl)].
A newly developed sustained-release form of orciprenaline-sulfate (Alupent) was tested in 13 patients. Determination of 3H-radioactivity in blood, urine and faeces was used to elucidate its pharmacokinetic properties. Maximum plasma levels of radioactivity were obtained between 8 and 12 h after administration. 10.7 +/- 2.5% of the administered radioactivity were excreted in urine over a period of 72 h. Orciprenaline was mainly excreted as the sulfate-conjugate. Approximately five percent of the radioactivity were excreted as 4,6,8-trihydroxy-N-isopropyl-tetrahydroisoquinoline--the condensation product of formaldehyde and orciprenaline.
D001711:Biotransformation; D003692:Delayed-Action Preparations; D005243:Feces / Q000032:analysis; D006801:Humans; D007700:Kinetics; D009921:Metaproterenol / Q000008:administration & dosage / Q000378:metabolism*; D008875:Middle Aged; D013997:Time Factors
D003692:Delayed-Action Preparations; D009921:Metaproterenol
Plasmaspiegel, renale Ausscheidung und Metabolismus von Orciprenalin nach Verabreichung als Depotpräparat.